Dr. Ayaka Nishikawa, Chief Director of Dermatology at Shonan Beauty Clinic, Leads a Session on REJURAN Injections for Doctors from Indonesia

Promoting international medical exchange to bring Japanese standards of care to Asia amid growing interest in skin-quality treatments

IRVINE, Calif. --SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced that Dr. Ayaka Nishikawa, Chief Director of Dermatology at Shonan Beauty Clinic, a clinic that receives management support from the Company, led a session for 15 doctors visiting Japan from Indonesia on REJURAN injections, a skin-quality treatment that aims to activate the skin’s regenerative capacity and support rejuvenation.

In recent years, demand for minimally invasive, non-surgical treatments has been growing in aesthetic healthcare, led by aesthetic dermatology. Interest in skin care has expanded considerably, and “skin-quality improvement” is becoming a widespread habit: the skin is gradually brought into better condition through regular maintenance centered on injectable and laser treatments.

With the aim of helping raise medical standards globally, 15 doctors practicing in Indonesia were welcomed for a session on REJURAN injections led by Dr. Nishikawa. REJURAN is an injectable treatment that uses salmon-derived polynucleotides (PN)* to promote the repair of skin cells damaged by aging and UV exposure and to help restore firmness and elasticity. Shonan Beauty Clinic is the only clinic in Japan to have received “DIAMOND” status, the highest tier in the clinic certification program of PharmaResearch, the medical manufacturer that supplies the product, in recognition of its usage (purchase) volume in Japan.

The session provided comprehensive instruction covering not only delicate injection techniques but also communication with customers. Participating doctors from Indonesia expressed high regard for the quality of the medical techniques and the thorough safety standards, and the session became an opportunity for meaningful exchange across borders. SBC Medical will continue to promote medical exchange with doctors in Japan and overseas and to expand its initiatives to deliver safe, reliable, and high-quality medical care.

For more information on REJURAN injections at Shonan Beauty Clinic, please visit here.

*Polynucleotides (PN): High-molecular-weight components derived from salmon DNA. With a viscous, three-dimensional structure, they are thought to act as a scaffold that supports tissue within the skin, and are used in injectable treatments aimed at improving skin texture and firmness.
Note: REJURAN injections are self-pay care and are not covered by Japan’s public health insurance. Treatment details, standard costs, treatment period and number of sessions, and principal risks and side effects are explained by the physician at the time of consultation.

About Dr. Ayaka Nishikawa

After graduating from the School of Medicine at Yokohama City University, Dr. Nishikawa joined Shonan Beauty Clinic in 2015 as an aesthetic dermatologist. In 2018, she was appointed Chief Director of Dermatology. She currently oversees a wide range of responsibilities across SBC Medical Group, including the development of aesthetic dermatology treatments, technical training for doctors and nurses, and safety management. She is also committed to promoting evidence-based medicine through the analysis of clinical cases, and actively engages in academic activities, including presentations at conferences in Japan and overseas and the authoring of research papers. In recognition of these achievements, she was appointed Visiting Professor at SBC Tokyo Medical University in 2023.
For more information on Dr. Nishikawa’s professional profile, please visit here.

About SBC Medical Group Holdings Incorporated
SBC Medical is a Medical Services Organization providing management support across a wide range of healthcare fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, hair loss treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.

For more information, visit https://sbc-holdings.com
For more insights and updates from SBC Medical, follow us on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s plans and strategies for service expansion; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” “targets” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.

Contacts
Hikaru Fukui / Head of IR Department; E-mail: ir@sbc-holdings.com
Akiko Wakiyama / Chief Public Relations Officer; E-mail: pr@sbc.or.jp